In summary, SEC61G drives an immunosuppressive, tumor-promoting microenvironment in brain metastases through the PGAM1-mediated glycolytic pathway, offering a potential therapeutic target to enhance anti-tumor immunity. This evidence concerns the gene PGAM1 and neoplasm.